Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads

BACKGROUND: Cytomegalovirus (CMV) can cause severe disease, including rejection in transplant recipients. Ganciclovir and its oral prodrug valganciclovir have been used as first-line therapy for CMV disease in transplant recipients. The exposure targets of ganciclovir are not exactly known, and toxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Märtson, Anne-Grete, Sturkenboom, Marieke G. G., Knoester, Marjolein, van der Werf, Tjip S., Alffenaar, Jan-Willem C., Hope, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809194/
https://www.ncbi.nlm.nih.gov/pubmed/35107143
http://dx.doi.org/10.1093/jac/dkab419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809194/
https://www.ncbi.nlm.nih.gov/pubmed/35107143
http://dx.doi.org/10.1093/jac/dkab419

Ejemplares similares